Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04763759 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections
A Phase 1 study, sponsored by Trellis Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04763759 is a Phase 1 study that has completed, run by Trellis Bioscience. The registered enrollment target is 15 participants.
The verdict
NCT04763759, a Phase 1 study, has completed, sponsored by Trellis Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making these pathogens substantially more susceptible to established antibiotic treatment regimens. This initial study is designed to assess overall safety and pharmacokinetics (PK) of TRL1068. The overall goal of the development program is to demonstrate that TRL1068 can facilitate effectiveness of a single stage joint replacement or preservation of the original infected prosthetic joint in a substantial proportion of patients with PJI.
Interventions
- DRUG TRL1068, a human monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-02-08 |
| Est. Completion | 2024-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04763759
The ClinicalTrials.gov registry entry for NCT04763759 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trellis Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRL1068, a human monoclonal antibody is the first listed.
NCT04763759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04763759 about?
NCT04763759 is a clinical study titled "Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections". TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making these pathogens substantially more susceptible to established antibiotic treatment regimens. This initial study is designed to assess overall safety and pharmacokinetics (PK) ...
What is the current status of trial NCT04763759?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-02-08. Estimated completion is 2024-03-13.
What interventions are being tested in trial NCT04763759?
The interventions under investigation include: TRL1068, a human monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT04763759?
This trial is sponsored by Trellis Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.